Please login to the form below

Not currently logged in
Email:
Password:

Merck & Co extends autoimmune collaboration with Lycera

New deal could be worth more than $300m to the US biopharma company

Merck & CoMerck & Co has extended its collaboration with Lycera to research new treatments for autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease and multiple sclerosis.

In addition to an undisclosed upfront fee, Lycera is eligible to receive more than $300m in milestone payments to build on an existing partnership focused on the development of therapies that target the retinoic acid related orphan receptor (RORyt).

This latest financial agreement is on top of the original deal, which consisted of an upfront payment of $12m and up to $295m in milestones, meaning Lycera could stand to make more than $600m from its deals with Merck.

The RORyt receptor at the heart of the agreements is responsible for the differentiation of T-helper 17 (Th17) cells, which produce the cytokine interleukin-17 (IL-17) that in turn, can lead to the development of autoimmune disorders.

It is thought that inhibiting RORyt could disrupt this process, reducing the production of IL-17.

Lycera has identified several inhibitors of RORyt, which Merck will take into clinical development, although no specific conditions to be targeted were named by either company.

Under the terms of the deal, Merck will gain commercialisation rights to any products developed as a result of the collaboration, while Lycera is entitled to receive royalty payments and milestones.

Rupert Vessey, senior VP, global scientific strategy at Merck Research Laboratories, explained why the company chose to expand its partnership.

“There are substantial unmet medical needs and opportunities in autoimmune disorders, and new targets representing attractive opportunities that we are very pleased to pursue through our new collaboration with Lycera,” he said.

Dr Kathleen Metters, Lycera's president and chief executive officer, was similarly enthusiastic: “We are absolutely delighted to expand our relationship with Merck, a collaboration that builds on the culture of scientific excellence fostered by both companies.”

14th February 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Door Communications

Red Door Communications (RDC) is the health and wellbeing communications consultancy that lives and breathes originality and is built on...

Latest intelligence

Online Physician Communities
M3 and partners win Digital Sales Aid Award
Wins for campaign to overcome limited doctor engagement with pharma-owned websites...
UK Customer Experience Awards 2014 Highlights
Stephanie Hall, Managing Director at Uptake Strategies, attended this year’s cross-industry UK Customer Experience Awards as a member of the judging panel for Business Transformation....
McCann3-thumb.jpg
The heart of the matter - Part Three
Is pharma doing enough to maximise real world evidence?...